(MRK) Merck - Ratings and Ratios
Keytruda, Gardasil, Januvia, Bovilis, Bravecto
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.09% |
| Yield on Cost 5y | 4.95% |
| Yield CAGR 5y | 5.91% |
| Payout Consistency | 93.7% |
| Payout Ratio | 37.9% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 27.4% |
| Value at Risk 5%th | 41.3% |
| Relative Tail Risk | -8.38% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -0.96 |
| CAGR/Max DD | 0.03 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.496 |
| Beta | 0.365 |
| Beta Downside | 0.469 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.44% |
| Mean DD | 15.67% |
| Median DD | 10.82% |
Description: MRK Merck September 24, 2025
Merck & Co., Inc. (ticker MRK) is a U.S.–based, globally operating healthcare company founded in 1891 and headquartered in Rahway, New Jersey, with business segments in human pharmaceuticals and animal health.
Its human-health portfolio spans oncology (Keytruda, Welireg, Zerbaxa, Noxafil), vaccines (Gardasil, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23), and chronic-disease therapies (Januvia/Janumet, Belsomra, Isentress, Adempas, Verquvo, Lagevrio, among others).
The animal-health division offers livestock products (Nuflor, Bovilis, Banamine, etc.) and companion-animal medicines (Bravecto, Sentinel, Nobivac, etc.), complemented by Allflex Livestock Intelligence digital solutions.
Merck maintains a network of strategic collaborations, including three deruxtecan ADC candidates with Daiichi Sankyo, co-development of Lynparza and Koselugo with AstraZeneca, licensing of the LM-299 bispecific antibody from LaNova, and partnerships with Eisai, Bayer, Ridgeback, Moderna, and Antengene to expand its oncology and immunotherapy pipeline.
Key financial and sector metrics: FY 2023 revenue reached approximately $59.3 billion, with Keytruda alone generating roughly $13 billion; R&D expenditure was about $9.5 billion (≈16 % of sales); animal health contributed ~ $5 billion. Primary growth drivers are an aging global population, rising cancer incidence, and sustained vaccine demand post-COVID-19, while pricing pressure in the U.S. and biosimilar competition pose ongoing risks.
For a deeper quantitative assessment of MRK’s valuation sensitivities and peer-adjusted multiples, the ValueRay platform offers a concise, data-driven dashboard worth exploring.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (19.03b TTM) > 0 and > 6% of Revenue (6% = 3.85b TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA -2.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 29.47% (prev 17.06%; Δ 12.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 17.07b <= Net Income 19.03b (YES >=105%, WARN >=100%) |
| Net Debt (23.20b) to EBITDA (27.57b) ratio: 0.84 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.50b) change vs 12m ago -1.69% (target <= -2.0% for YES) |
| Gross Margin 78.32% (prev 75.82%; Δ 2.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.00% (prev 53.75%; Δ -1.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.43 (EBITDA TTM 27.57b / Interest Expense TTM 1.18b) >= 6 (WARN >= 3) |
Altman Z'' 4.96
| (A) 0.15 = (Total Current Assets 47.56b - Total Current Liabilities 28.63b) / Total Assets 129.55b |
| (B) 0.56 = Retained Earnings (Balance) 72.23b / Total Assets 129.55b |
| (C) 0.19 = EBIT TTM 23.00b / Avg Total Assets 123.54b |
| (D) 0.89 = Book Value of Equity 68.82b / Total Liabilities 77.64b |
| Total Rating: 4.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.20
| 1. Piotroski 5.50pt |
| 2. FCF Yield 5.01% |
| 3. FCF Margin 20.31% |
| 4. Debt/Equity 0.80 |
| 5. Debt/Ebitda 0.84 |
| 6. ROIC - WACC (= 16.59)% |
| 7. RoE 38.95% |
| 8. Rev. Trend 70.33% |
| 9. EPS Trend 13.51% |
What is the price of MRK shares?
Over the past week, the price has changed by +7.23%, over one month by +20.45%, over three months by +27.23% and over the past year by +6.96%.
Is MRK a buy, sell or hold?
- Strong Buy: 12
- Buy: 3
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 102.9 | -1.8% |
| Analysts Target Price | 102.9 | -1.8% |
| ValueRay Target Price | 108.5 | 3.5% |
MRK Fundamental Data Overview November 22, 2025
P/E Trailing = 12.5622
P/E Forward = 10.1112
P/S = 3.6929
P/B = 4.55
P/EG = 1.0012
Beta = 0.319
Revenue TTM = 64.23b USD
EBIT TTM = 23.00b USD
EBITDA TTM = 27.57b USD
Long Term Debt = 39.97b USD (from longTermDebt, last quarter)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 41.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.20b USD (from netDebt column, last quarter)
Enterprise Value = 260.37b USD (237.21b + Debt 41.37b - CCE 18.21b)
Interest Coverage Ratio = 19.43 (Ebit TTM 23.00b / Interest Expense TTM 1.18b)
FCF Yield = 5.01% (FCF TTM 13.05b / Enterprise Value 260.37b)
FCF Margin = 20.31% (FCF TTM 13.05b / Revenue TTM 64.23b)
Net Margin = 29.63% (Net Income TTM 19.03b / Revenue TTM 64.23b)
Gross Margin = 78.32% ((Revenue TTM 64.23b - Cost of Revenue TTM 13.93b) / Revenue TTM)
Gross Margin QoQ = 81.92% (prev 77.50%)
Tobins Q-Ratio = 2.01 (Enterprise Value 260.37b / Total Assets 129.55b)
Interest Expense / Debt = 0.58% (Interest Expense 238.0m / Debt 41.37b)
Taxrate = 14.20% (958.0m / 6.75b)
NOPAT = 19.73b (EBIT 23.00b * (1 - 14.20%))
Current Ratio = 1.66 (Total Current Assets 47.56b / Total Current Liabilities 28.63b)
Debt / Equity = 0.80 (Debt 41.37b / totalStockholderEquity, last quarter 51.85b)
Debt / EBITDA = 0.84 (Net Debt 23.20b / EBITDA 27.57b)
Debt / FCF = 1.78 (Net Debt 23.20b / FCF TTM 13.05b)
Total Stockholder Equity = 48.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.69% (Net Income 19.03b / Total Assets 129.55b)
RoE = 38.95% (Net Income TTM 19.03b / Total Stockholder Equity 48.87b)
RoCE = 25.89% (EBIT 23.00b / Capital Employed (Equity 48.87b + L.T.Debt 39.97b))
RoIC = 22.93% (NOPAT 19.73b / Invested Capital 86.06b)
WACC = 6.34% (E(237.21b)/V(278.59b) * Re(7.36%) + D(41.37b)/V(278.59b) * Rd(0.58%) * (1-Tc(0.14)))
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.11%
[DCF Debug] Terminal Value 78.94% ; FCFE base≈13.77b ; Y1≈14.41b ; Y5≈16.75b
Fair Price DCF = 118.4 (DCF Value 293.77b / Shares Outstanding 2.48b; 5y FCF grow 5.00% → 3.0% )
EPS Correlation: 13.51 | EPS CAGR: 10.08% | SUE: 3.25 | # QB: 3
Revenue Correlation: 70.33 | Revenue CAGR: 6.75% | SUE: 0.60 | # QB: 0
Additional Sources for MRK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle